ClinicalTrials.Veeva

Menu

Hypoxia-induced Autophagy in the Pathogenesis of MAP

A

Assiut University

Status

Not yet enrolling

Conditions

Placenta
Autophagy
Morbidly Adherent Placenta
Hypoxia

Treatments

Diagnostic Test: HIF 1α and LC3B expression and MMP-9 level

Study type

Observational

Funder types

Other

Identifiers

NCT05817448
hypoxia in MAP

Details and patient eligibility

About

To investigate the role of HIF 1α and LC3B in the pathogenesis of MAP, to evaluate the role of MMP-9 in the antenatal prediction of MAP, and to compare the expression of HIF1α, LC3B, and level MMP-9 between patients of placenta previa with MAP and patients with normal placentation.

Full description

Cesarean section (CS) rate has been rising rapidly in the recent years.One of the complications of repeated CS is placenta previa, an implantation of placenta on or near internal os.

Morbidly adherent placenta (MAP), known also as placenta accreta spectrum, has histopathologic and clinical types. The placenta becomes abnormally adherent to the uterine wall, fails to separate leading to massive blood loss and possible hysterectomy. The risk of MAP in patient with placenta previa increases with repeated CS.

Theories for development of MAP include abnormal trophoblastic invasion of myometrium, abnormal decidualization, neovascularization and reduction of apoptosis of trophobalsts.

In early pregnancy: the trophoblasts invade spiral arteries and reduce blood flow to the placenta 00leading to hypoxia. Hypoxia inducible factor 1 alpha (HIF-1α), a protein involved in cellular adaptation to hypoxia, increases throughout pregnancy and contributes in the invasion of trophoblasts. Excessive invasion in MAP might prolong the hypoxia, increasing the expression of HIF1α.

Autophagy is a process for managing and removing the damaged organelles and cellular proteins in hypoxia. It supports the trophoblasts. Hypoxia induced autophagy markers such as LC3B might be enhanced by MAP.

Matrix metalloproteinase-9 (MMP-9) plays an important role in cell invasion and placental implantation. Disturbance of MMP-9 might alter the trophobalsts invasion resulting in MAP .

The investigators hypothesize that hypoxia, autophagy and invasiveness are linked to the pathophysiology of MAP, so we will assess the expression of HIF1α, LC3B to estimate their role beside MMP-9.

Enrollment

80 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Gestational age: more than 28 weeks up to 40 weeks.
  2. Pregnant women with at least one previous CS.
  3. Singleton pregnancy.
  4. Patient known to have placenta previa by 2D ultrasound.
  5. Heamodynamically stable patient.

Exclusion criteria

  1. Multiple pregnancy.
  2. Gestational age less than 28 weeks.
  3. Heamodynamically unstable patient.
  4. Hypertensive disorder with pregnancy.
  5. Gestational diabetes.
  6. IUGR.
  7. Patient with bleeding tendency or using anticoagulant.

Trial design

80 participants in 2 patient groups

control group
Description:
40 pregnant women with normal placentation having no pregnancy related disorders according to the physical examination and laboratory findings.
Treatment:
Diagnostic Test: HIF 1α and LC3B expression and MMP-9 level
placenta previa group
Description:
40 pregnant women that will be diagnosed according to the ultrasound diagnostic criteria. Then according to the histopathological examination, placenta previa group will be subdivided into 2 groups, placenta previa with MAP and placenta previa without MAP
Treatment:
Diagnostic Test: HIF 1α and LC3B expression and MMP-9 level

Trial contacts and locations

0

Loading...

Central trial contact

Nermeen Bahaa ElDien Mohamed Ahmed, dr; Dalia Gamal El-Din Mostafa Morsy, prof dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems